



Galectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

04/02/19

NORCROSS, Ga., April 02, 2019 (GLOBE NEWSWIRE) -- [Galectin Therapeutics Inc.](http://www.galectintherapeutics.com) (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold Shlevin, the Company's President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference, on Tuesday, April 9, 2019, at 9:30 a.m. GMT (5:30 a.m. EDT). The conference is being held at the Grosvenor House in London.

A live webcast of the presentation may be accessed on the conference's website at <http://www.wsj.com/webcast/hcw4/galt/>. Following the live presentation, the webcast will be archived at www.galectintherapeutics.com.

About Galectin Therapeutics

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are for treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.

Investor Contact:

Galectin Therapeutics Inc.
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com

Media Contact:

Gregory FCA
Rachel Giltz, Senior Account Executive
(215) 297-3607
rachel@gregoryfca.com



Source: Galectin Therapeutics Inc.